Clinical Trials Logo

Filter by:
NCT ID: NCT03197272 Completed - Myopia Clinical Trials

Advanced Cross Linking for Low-grade Myopia

PiXLO2
Start date: April 21, 2016
Phase: N/A
Study type: Interventional

To evaluate the improvement in myopic refractive error and the corneal endothelial safety with a corneal crosslinking treatment regimen for mild myopia. The treatment involves a 4-mm central treatment zone in high oxygen environment without corneal epithelial debridement.

NCT ID: NCT03196713 Completed - Clinical trials for Autism Spectrum Disorder

Early Intervention, Supervision, Quality and Outcome in ASD

Start date: April 1, 2013
Phase: N/A
Study type: Interventional

The objective of this study is to examine the significance of knowledge of autism spectrum disorder (ASD), and early intensive behavioral intervention, as well as trust in EIBI, adequate assessment of EIBI quality, and EIBI supervision on EIBI intervention outcome in ASD.

NCT ID: NCT03196297 Completed - Haemophilia A Clinical Trials

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

explorerâ„¢5
Start date: August 16, 2017
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.

NCT ID: NCT03196284 Completed - Clinical trials for Congenital Bleeding Disorder

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

explorerâ„¢4
Start date: August 10, 2017
Phase: Phase 2
Study type: Interventional

This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.

NCT ID: NCT03193671 Completed - Ovarian Neoplasms Clinical Trials

Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis

Start date: September 1, 2013
Phase: N/A
Study type: Observational [Patient Registry]

This study evaluates the biomarkers CA125 and HE4 and the algorithms RMI and ROMA on a normal population in the western region of Sweden. The aim is to improve diagnosis of ovarian cancer. If the investigators observe a clear improvement in the early diagnosis of EOC, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of Sweden.

NCT ID: NCT03192930 Completed - Saturation Exposure Clinical Trials

Inflammatory and Cerebrospinal Biochemical Markers in Blood During Prolonged Hyperbaric Exposure

Mättnad2017
Start date: March 17, 2017
Phase:
Study type: Observational

Research hypothesis - Prolonged hyperbaric exposure will affect the central nervous system - Prolonged hyperbaric exposure will induce inflammatory changes - Prolonged hyperbaric exposure will affect fluid regulation in the body Objectives: - To investigate the presence of cerebrospinal biochemical markers in blood during prolonged hyperbaric exposure - To investigate changes in the quantity of cerebrospinal biochemical markers in blood during decompression after prolonged hyperbaric exposure - To investigate the presence of inflammatory markers in blood during prolonged hyperbaric exposure - To investigate changes in the quantity of inflammatory markers in blood during decompression after prolonged hyperbaric exposure - To investigate if prolonged hyperbaric exposure alters fluid balance in the body

NCT ID: NCT03191799 Completed - Hemophilia A Clinical Trials

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

STASEY
Start date: September 5, 2017
Phase: Phase 3
Study type: Interventional

This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.

NCT ID: NCT03191396 Completed - Clinical trials for Diabetes Mellitus, Type 2

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

SUSTAIN 10
Start date: June 27, 2017
Phase: Phase 3
Study type: Interventional

This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes. The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at the clinic and 3 phone calls with the study doctor. At the visits, participants will have a number of tests, for example: general health checks, blood samples, heart and eye checks etc. Participants will also fill in some forms about their health and satisfaction with their diabetes treatment.

NCT ID: NCT03190252 Completed - Inflammation Clinical Trials

Inflammatory and Cerebrospinal Biochemical Markers in Blood After Trimix Diving

TriMix17-18
Start date: June 12, 2017
Phase:
Study type: Observational

Research hypothesis - Diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas will affect the central nervous system. - Diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas will induce inflammatory changes. Objectives: - To investigate the presence of cerebrospinal biochemical markers in blood after diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas. - To investigate the presence of inflammatory markers in blood after diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas. - To investigate the presence of venous gas emboli (VGE) in blood after diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas.

NCT ID: NCT03190018 Completed - Peritoneal Dialysis Clinical Trials

A Feasibility Study of Peritoneal Dialysis With CLS PD, Which Removes Toxins and Maintains a Stable Ultrafiltration by Continuously Regenerating a Recirculating Intraperitoneal Fluid, in Patients With End Stage Renal Disease, ESRD, With PD Therapy.

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The study is a proof-of-concept of peritoneal dialysis with the Carry Life System for Peritoneal Dialysis (CLS PD). The extra-corporeally absorption of uremic toxins and certain ions from the recirculated peritoneal fluid by the Purcart are evaluated together with the achievement of a stable intraperitoneal osmolarity.